Results from CHAMPION-NMOSD trial demonstrated zero relapses with a median treatment duration of 73 weeks
Additional presentations will underscore debilitating emotional and physical toll of NMOSD on patients and caregivers, and highlight urgency to reduce disease burden
Attachments
Disclaimer
AstraZeneca plc published this content on 12 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2022 09:09:11 UTC.
